glp-1 drugs safety Researchers find medications safe to continue before surgery in patients with diabetes and obesity The GLP-1 Agonists and Obesity:

Learn about the Ozempic blindness lawsuit, including NAION and other vision problems, and read about the study linking semaglutide use to severe eye problems.

The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer

GLP-1 drugs like Ozempic and Mounjaro may offer real benefits for people with type 1 diabetes: less insulin, flatter CGM curves, and emerging evidence for heart and kidney protection.

Patients should not automatically stop their long-acting insulin when starting a GLP-1 receptor agonist, but the insulin dose should be reduced by 20% initia...

In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c6.5%